2025-04-17 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Report

**0. Executive Summary:**

Teladoc Health Inc. (TDOC) is a virtual healthcare company providing telehealth services.  The stock has significantly underperformed the S&P 500 (VOO) over the analyzed period, showing substantial negative returns. Recent financial performance reveals mixed signals, with relatively stable revenue but fluctuating and largely negative profitability metrics.  Technical indicators suggest a bearish sentiment.

**1. Performance Comparison & Alpha/Beta Analysis:**

TDOC's cumulative return is -70.77%, significantly lagging behind the S&P 500's 71.51% return. The difference is -142.3%, placing it at the 4.7th percentile of the historical range of divergence between TDOC and VOO.


The Alpha/Beta analysis reveals high volatility and inconsistent performance. While CAGR was high in some periods,  the recent years (2019-2025) demonstrate substantial negative returns, even reaching -488% CAGR in the 2021-2023 period.  Beta values fluctuate widely, suggesting significant market sensitivity but inconsistent sensitivity over time.  Market capitalization has also drastically declined in recent years.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 76.0% | 60.6% | 49.0% | 0.0 | 6.1 |
| 2016-2018  | 128.0% | 59.3% | 109.0% | 0.0 | 8.7 |
| 2017-2019  | 176.0% | 59.3% | 145.0% | 0.4 | 14.7 |
| 2018-2020  | 237.0% | 64.0% | 208.0% | 0.2 | 35.0 |
| 2019-2021  | -83.0% | 64.0% | -141.0% | 0.2 | 16.1 |
| 2020-2022  | -295.0% | 81.3% | -303.0% | 0.0 | 4.2 |
| 2021-2023  | -488.0% | 81.3% | -508.0% | -0.6 | 3.8 |
| 2022-2024  | -111.0% | 81.3% | -131.0% | -0.9 | 1.6 |
| 2023-2025  | -41.0% | 72.9% | -55.0% | -0.9 | 1.2 |


**2. Recent Price Movement:**

* **Closing Price:** $6.90
* **Last Day Change:** -3.36%  (Significant daily drop)
* **5-Day Moving Average:** $7.15
* **20-Day Moving Average:** $7.79
* **60-Day Moving Average:** $9.68

The price is below all three moving averages, indicating a bearish trend.  The large negative daily change suggests a possible catalyst for the recent downward movement warrants further investigation.

**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.41 (Medium Risk)
* **RSI:** 23.9 (Oversold; indicating potential bounce, but not necessarily a buy signal)
* **PPO:** -0.13 (Negative, suggesting bearish momentum)
* **20-Day Relative Strength Divergence:** -0.2 (Short-term downtrend)
* **Expected Return:** -1845.2% (This extremely negative figure suggests a highly pessimistic outlook relative to the S&P 500 for long-term investment.  This needs further clarification of the calculation methodology).


**4. Recent Earnings Analysis:**

Teladoc's recent earnings show persistent net losses. Revenue has remained relatively flat, but EPS is significantly negative.  Further investigation is needed to understand the reasons for the consistent losses, particularly given the relatively stable revenue figures.


| Date       | EPS    | Revenue      |
|------------|--------|---------------|
| 2024-10-31 | -$0.19 | $0.64 B      |
| 2024-08-01 | -$4.92 | $0.64 B      |
| 2024-04-26 | -$0.49 | $0.65 B      |
| 2023-10-27 | -$0.35 | $0.66 B      |
| 2024-10-31 | -$0.35 | $0.66 B      |


**5. Financial Information:**

Revenue is relatively stable, but profit margins, while high, do not translate to positive net income.  Equity and Return on Equity (ROE) are fluctuating and show negative values in most recent quarters.  This suggests issues with profitability and potentially efficiency problems.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.64B | 70.50% |
| 2024-09-30 | $0.64B | 71.94% |
| 2024-06-30 | $0.64B | 70.73% |
| 2024-03-31 | $0.65B | 69.89% |
| 2023-12-31 | $0.66B | 70.72% |


**Capital and Profitability:**

| Quarter | Equity | ROE     |
|---------|---------|---------|
| 2024-12-31 | $1.49B | -3.25%  |
| 2024-09-30 | $1.51B | -2.21%  |
| 2024-06-30 | $1.50B | -55.77% |
| 2024-03-31 | $2.29B | -3.58%  |
| 2023-12-31 | $2.33B | -1.24%  |


**6. Overall Analysis:**

TDOC's performance has been significantly negative, dramatically underperforming the S&P 500. While revenue has been relatively stable, the company is experiencing substantial losses, as evidenced by negative EPS and ROE. Technical indicators point towards a bearish trend.  The extremely negative expected return figure requires further scrutiny to understand its calculation and implications.  Before considering any investment, a thorough investigation into the reasons for the company's persistent losses and the future outlook for the telehealth market is crucial.  The high volatility and negative performance raise significant concerns about the risk associated with this investment.  Further due diligence is absolutely necessary before making any investment decision.
